Genetically-informed Therapy for ER+ Breast Cancer in a Post-CDK4/6 Inhibitor Setting: a Phase II Umbrella Study (GERTRUDE)
This study is testing different drug combinations to see which ones work best for advanced breast cancer. It focuses on patients whose cancer has grown after receiving a specific type of previous treatment.
You may be able to join if you are a postmenopausal woman aged 18 or older with estrogen receptor-positive breast cancer that has spread, and you have previously been treated with certain targeted drugs like palbociclib, ribociclib, or abemaciclib.
Participants will receive a personalized combination of medications, such as hormone therapy or targeted cancer drugs, chosen based on their genetic profile. Your health and the cancer's response will be closely monitored throughout the process.
This study is currently recruiting participants in Lebanon, New Hampshire, United States.
- 1Evaluates new drug combinations for advanced breast cancer
- 2Tailored for patients who have already tried certain initial targeted therapies
- 3Currently recruiting patients in Lebanon, New Hampshire
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.